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Summary
Objective: To describe our experience of post-transplant infections in allogeneic stem cell
transplants at the Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan.
Methods: From July 2001 to September 2006, patients with malignant and non-malignant
hematological disorders having human leukocyte antigen (HLA)-matched sibling donors were
selected for transplant. Pre-transplant infection surveillance was carried out, and strict pro-
phylaxis against infection was observed. After admission to the hospital, patients were kept in
protective isolation rooms, equipped with a HEPA filter positive-pressure laminar airflow ventila-
tion system. Bone marrow and/or peripheral blood stem cells were used as the stem cell source.
Cyclosporin and prednisolone were used as prophylaxis against graft-versus-host disease (GVHD).
The engraftment was monitored with cytogenetic/molecular analysis and change of blood group.
Survival was calculated from the date of transplant to death or last follow-up.
Results: One hundred and fifty-four patients received allogeneic stem cell transplants from HLA-
matched siblings for various hematological disorders at the Armed Forces Bone Marrow Transplant
Centre, Rawalpindi, Pakistan between July 2001 and September 2006. Indications for transplant
included aplastic anemia (n = 66), b-thalassemia major (n = 40), chronic myeloid leukemia
(n = 33), acute leukemia (n = 8), and miscellaneous disorders (n = 7). One hundred and twenty
patients weremale and 34 were female. Themedian age of the patient cohort was 14 years (range
11/4 54 years). One hundred and thirty-six patients and 135 donors were cytomegalovirus (CMV)
IgG-positive. One hundred and forty patients (90.9%) developed febrile episodes in different
phases of post-transplant recovery. Infective organisms were isolated in 150 microbiological
culture specimens out of 651 specimens from different sites of infections (23.0% culture
positivity). Post-transplant infections were confirmed in 120 patients (77.9%) on the basis of
clinical assessment andmicrobiological, virological, and histopathological examination. Mortality
related to infections was 13.0%. Fatal infections included CMV disease (100% mortality, 6/6),
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disseminated aspergillosis (66.7% mortality, 4/6), pseudomonas septicemia (42.9% mortality, 9/21),
and tuberculosis (25% mortality, 1/4).
Conclusions: More than 90% of our patients developed febrile episodes with relatively low culture
yield. The majority of infections were treated effectively, however CMV, aspergillosis, and pseu-
domonas infections remained problematic with high mortality.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Stem cell transplantation (SCT) is the most effective treat-
ment for hematological disorders. Opportunistic infections
are one of the main causes of morbidity and mortality after
SCTand the successful outcome of SCT is largely determined
by infectious complications. According to International Bone
Marrow Transplant Registry (IBMTR) data for the period
1996—2000, infections contributed to 17% of deaths in allo-
geneic SCT and 21% in autologous SCT.1
The epidemiology of these infections depends on the
degree, type, and duration of immune suppression, the
use of prophylactic antibiotics, surveillance for organisms
associated with nosocomial infections, the emergence of
drug-resistant organisms, and the use of isolation precau-
tions.2 The relative frequencies of opportunistic pathogens
vary at different periods post-SCT. Therefore it is important
to define the pattern of infectious complications at different
times after SCT.3 Factors that influence the risk of infections
include mucosal damage, presence of a right atrial catheter,
and prolonged neutropenia prior to SCT. The role of graft-
versus-host disease (GVHD) and its treatment in the patho-
genesis of these infections has been well documented.4
Bloodstream infections in patients with profound neutro-
penia are associated with prolonged hospitalization and poor
short-term survival. Systemic fungal infections are serious
complications as they carry higher morbidity and mortality
compared with frequently isolated nosocomial blood-borne
pathogens such as Staphylococcus aureus and Pseudomonas
aeruginosa, etc.5 Systemic candidiasis is a serious complica-
tion associated with high morbidity and mortality. Antifungal
prophylaxis with fluconazole during the early post-transplant
period has been shown to significantly reduce the incidence
of candidemia and improve short-term survival. Nosocomial
fungemia due to Candida species has steadily increased over
the past four decades in SCT recipients.6
For decades, various approaches have been undertaken in
an attempt to reduce the risk of translocated oral and bowel
flora, which, along with central venous catheters are the
source of serious infections in SCT patients through the years.
Numerous regimens have been tried, including neomycin and
polymyxin, trimethoprim—sulfamethoxazole (TMP—SMX),
and most recently, the oral quinolones, particularly cipro-
floxacin. Although the practice of oral prophylaxis is routine
in many SCT centers, the current problems with drug resis-
tance may force a careful reconsideration of this still unpro-
ven approach.7,8
Cytomegalovirus (CMV) infection remains one of the most
important complications of allogeneic SCT, although the
impact on morbidity and mortality has been reduced during
the last decade by improvements in management. The dif-
ferent preventive strategies for CMV disease include use ofthe appropriate blood products, immunoglobulin, and use of
antiviral agents either as chemoprophylaxis or pre-emptive
therapy. The currently available antiviral agents for the
prevention of CMV infection and to treat disease are acyclo-
vir, valacyclovir, ganciclovir, valganciclovir, foscarnet, and
cidofovir.9—11
The Armed Forces Bone Marrow Transplant Centre has
provided bone marrow transplant facilities in Pakistan since
2001. The bone marrow transplant program is in the evolu-
tionary stages in this country and no consolidated data have
yet been published. With this background we describe herein
our initial experiences of post-transplant infectious compli-
cations in various malignant and non-malignant hematologi-
cal disorders for the period from July 2001 to September
2006.
Patients and methods
Patients with malignant and non-malignant hematological
disorders having human leukocyte antigen (HLA)-matched
sibling donors were selected for transplant. The age limit
for b-thalassemia major, Gaucher’s disease, and Fanconi’s
anemia was 14 years. For aplastic anemia, the age limit was
40 years, and for myelodysplastic syndrome (MDS), acute
leukemias, chronic myeloid leukemia (CML), and lymphomas,
the age limit was 55 years. These patients were stratified into
different risk groups according to well-established criteria.
Patients with aplastic anemia were categorized into severe
and very severe aplastic anemia on the basis of degree of
pancytopenia and marrow cellularity according to Camitta
criteria. Patients with b-thalassemia major were categorized
into risk classes I, II, and III on the basis of presence or
absence of hepatomegaly, degree of fibrosis on liver biopsy,
and adequacy of iron chelation according to Lucarelli’s
Pesaro group risk classification. Patients with CML were
classified into standard and high risk on the basis of duration
of disease, phase of disease, response to therapy, age, and
patient/donor sex combination according to European Group
for Blood and Marrow Transplantation (EBMT) risk stratifica-
tion criteria.
Pre-transplant infection surveillance
As per our transplant protocol, after HLA-typing all patients
and sibling donors underwent pre-transplant infection sur-
veillance. Prospective surveillancewas carried out to detect
the spectrum of microbial pathogens in our patients and to
treat them with appropriate antibiotics. Surveillance cul-
tures were taken from the nose, throat, stool, and urine for
the pattern of organisms involved, particularly methicillin-
resistant Staphylococcus aureus (MRSA), Streptococcus
spp, Salmonella spp, Shigella spp, and enteropathogenic
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microscopically for intestinal parasites including Entamoeba
histolytica, Giardia lamblia, intestinal flagellates, hel-
minths, and Cryptosporidium.
Peripheral blood films were screened for malarial para-
sites by conventional microscopy after preparing thick and
thin Giemsa-stained peripheral blood smears. All patients
and donors were screened for tuberculosis by Mantoux test
and chest X-ray, while sputum for acid-fast bacilli (AFB)
examination and PCR for Mycobacterium tuberculosis were
done in suspicious cases. As per our anti-tuberculosis treat-
ment policy, patients and/or donors with a positive Mantoux
test or with active tuberculosis received four-drug anti-
tuberculosis therapy (rifampin, isoniazid, pyrazinamide,
and ethambutol) for at least two months. After re-evaluation
these patients were subjected to allogeneic SCT, and anti-
tuberculosis therapy was continued for another 6 months
post-transplant.
Virological screening for hepatitis B, hepatitis C, HIV, CMV,
and Epstein—Barr virus (EBV) was carried out by ELISA and
molecular analysis (PCR) where indicated. All patients with
positive hepatitis B, hepatitis C, and HIV results were con-
sidered unfit for transplant. Virological screening for hepa-
titis B virus (HBV) was done by testing for hepatitis B surface
antigen (HBsAg) and anti-hepatitis B core antigen (anti-HBc)
using the MONOLISA plus enzyme immunoassay kit (Bio-Rad).
All HBsAg- and anti-HBc-negative patients were subjected to
transplant, while HBsAg- and anti-HBc-positive patients were
further tested for HBV-DNA by real-time PCR (Sacace Bio-
technologies, Italy). These patients, however, were consid-
ered unfit for transplant. Hepatitis C virus (HCV) screening
was done by testing for anti-HCV antibodies by ELISA (Innot-
est HCV Ab IV, Italy; fourth generation enzyme immunoassay
kit). HCV-RNA was tested for by PCR using QIAamp viral RNA
kit (Qiagen, Germany). Anti-HCV-positive patients with nor-
mal ALT and negative PCR were subjected to transplant,
while HCV PCR-positive patients were considered unfit for
transplant. CMV antigenemia testing was done by CMV Brite
Kit (IQ Corporation B.V., The Netherlands) to detect CMV
antigen PP65 in peripheral blood polymorphonuclear (PMN)
cells, and CMV PCR was performed using CMV Real-TM Quant
RG real-time kit for quantitative CMV PCR (Corbett Research
and Sacace Biotechnologies, Italy). Test results of 20 000
copies/ml were considered positive. CMV antigenemia was
monitored weekly for the first 100 days by ELISA and CMV
molecular analysis and thereafter monthly for one year. Pre-
transplant screening for Varicella zoster virus (VZV) was
carried out by indigenously manufactured complement fixa-
tion test (CFT). These tests were performed in pre-transplant
assessment only to detect high-risk patients. VZV-positive
patients were given acyclovir prophylaxis in high doses for
longer duration (9 months). Pre-transplant screening for EBV
was carried out by EBV viral capsid antigen (VCA) IgM enzyme
immunoassay by using DIA PRO diagnostic bioprobes (Srl,
Italy).
After admission to the hospital, patients were kept in
protective isolation rooms, equipped with a HEPA filter posi-
tive-pressure laminar airflow ventilation system. Clinical
examination of patients was performed twice a day as well
as when required. All patients were provided with a bacteria-
reduced diet. Leuko-depleted and irradiated blood products
were used during the post-transplant period.Antimicrobial protocol
Antimicrobial prophylaxis consisted of ciprofloxacin 250—
500 mg twice daily (10—30 mg/kg daily in two divided doses)
from the start of conditioning for gut decontamination.
Empiric broad-spectrum anti-pseudomonal penicillin in com-
bination with aminoglycoside was started once neutropenic
patients developed febrile spikes as defined. These consisted
of piperacillin—tazobactam 4.5 g IV 6-hourly (adults and
children >12 years) or 90 mg/kg 6-hourly (children <50 kg)
along with amikacin 15 mg/kg/day. Blood cultures were
taken at the start of fever and whenever antibiotics were
changed. Results of bacteriological cultures were usually
available by the third day. In culture-negative patients
who had persisting symptoms, antibiotics were changed on
the fifth day.
Fluconazole 50—100 mg daily (3—6 mg/kg daily) and acy-
clovir 250—500 mg three time a day (5 mg/kg three times
daily) were used as antifungal and antiviral prophylaxis,
respectively, starting at day 2, continuing until day +180.
Patients who required antifungals in therapeutic doses were
given amphotericin 1.0—1.5 mg/kg/day. Patients with a con-
firmed fungal infection responding poorly to amphotericin or
developing deranged renal functions were given either vor-
iconazole or caspofungin depending on availability. Acyclovir
was switched to therapeutic doses upon confirmation/strong
suspicion of susceptible viral infection. Prophylaxis for CMV
infection consisted of acyclovir at a dose of 10 mg/kg three
times daily from day2 to day +180. Once the antigenemia or
rising copies of CMV PCR was confirmed, pre-emptive anti-
viral therapy with ganciclovir was started at 5 mg/kg every
12 hours for 14 days or until 7 days after the clearance of CMV
antigen from blood, whichever was later, and then ganciclo-
vir (5 mg/kg/day) continued for the next 14 days. CMV dis-
ease was treated with ganciclovir (5 mg/kg every 12 hours)
for three weeks followed by 5 mg/kg/day for the next 4
weeks.
Pentamidine sulfate (300 mg) nebulization monthly was
used as prophylaxis for Pneumocystis jiroveci infection at the
time of conditioning. TMP—SMX combination was used as
prophylaxis after hematological recovery and continued
for 9 months post-transplant. Chloroquine sulfate 250—
500 mg (10—15 mg/kg) weekly was used as prophylaxis
against malaria and continued for 6 months post-transplant.
Amoebic dysentery, giardiasis, and helminthic infestations
are quite prevalent in our country, so all patients also
received metronidazole 200—400 mg three times daily
(7.5 mg/kg three times a day) for 7 days and albendazole
(200—400 mg) as a single dose before transplant.
Documentation of infections and definitions
Neutropenia was defined as an absolute neutrophil count
(ANC) <0.5  109/l and was considered to have ended at
an ANC >1.0  109/l. An infection was defined as nosocomial
when there was no evidence of infection at the time of
admission to the hospital. A febrile temperature spike of
>38 8C on two occasions 30 minutes apart or >39 8C on one
occasion in neutropenic patients was considered as febrile
neutropenia. A blood stream infection (BSI) was definedwhen
the pathogen was isolated from blood culture and was not
related to infection at another site. Blood culture samples
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peripheral vein. Single blood culture isolates were sufficient
to classify a febrile episode as bacteremia. Catheter-asso-
ciated sepsis was defined as primary sepsis if there were signs
of infection at the insertion site of an intravascular catheter
and one of the following: (1) fever >38 8C, (2) chills, (3)
hypotension. Pneumonia was defined as fever >38 8C, pro-
duction of sputum, cough, dyspnea, ronchi/rales, or pleural
rub with radiological evidence/organism isolated from
bronchoalveolar lavage (BAL) or cultured from blood. A soft
tissue infection was defined when there was localized pain,
redness, swelling, or purulent discharge with positive culture
from the site involved. Disseminated aspergillosis was
defined when Aspergillus infection was established at more
than one site. Pneumocystis jiroveci (carinii) pneumonitis
(PCP) was defined when radiological evidence of pneumonitis
was combined with isolation of P. jiroveci from induced
sputum or BAL fluid. We designed consensus definitions for
CMV antigenemia, CMV infection, CMV disease, and CMV
syndrome. CMV antigenemia was defined as detection of
CMVantigen in blood. CMV infection was defined as detection
of CMV antigen in blood with signs of respiratory or gastro-
intestinal system symptoms (pneumonia/diarrhea) without
detection of CMV antigen from the appropriate tissue speci-
men. CMV disease was defined as patients having detectable
CMV antigenemia along with appropriate tissue diagnosis.
CMV syndrome was defined by fever, pancytopenia, and CMV
antigenemia. CMV pneumonia was defined by the presence of
cough, fever, and dyspnea combined with radiological evi-
dence of lung infiltrates and detection of CMV in BAL. CMV
enteritis was defined by the presence of diarrhea and detec-
tion of CMV in involved gut biopsy. Infection-related mortal-
ity was defined as the death rate associated with
disseminated bacterial, viral, and fungal infections.
Transplant procedures
Patients with aplastic anemia received lymphoglobulin (SANG
Stat, Lyon, France) 15 mg/kg daily for 3 days (total dose
45 mg/kg) and cyclophosphamide 50 mg IV daily for four days
(total dose 200 mg/kg). Patients with thalassemia (class I and
class II) and Gaucher’s disease received conditioning with
busulfan 3.5 mg/kg PO in divided doses daily for four days
(total dose 14 mg/kg) followed by cyclophosphamide 50 mg/
kg once daily IV for four days (total dose 200 mg/kg). Class III
thalassemic patients received long-duration conditioning
with hydroxyurea 30 mg/kg daily and azathioprine 3 mg/kg
daily (from day 45 to day 11), fludarabine 20 mg/m2 daily
(from day17 to day11), busulfan 3.5 mg/kg PO in divided
doses daily for four days (total dose 14 mg/kg), followed by
cyclophosphamide 40 mg/kg once daily IV for four days (total
dose 160 mg/kg). Patients with acute leukemias and CML
received busulfan 4 mg/kg daily for four days (total dose
16 mg/kg), followed by cyclophosphamide either 40 mg/kg
daily for four days (total dose 200 mg/kg) or 60 mg/kg daily
for two days in high-risk CML patients (total dose 120 mg/kg).
Patients with Fanconi’s anemia received lymphoglobulin
15 mg/kg daily for three days (total dose 45 mg/kg), fludar-
abine 30 mg/m2 daily for 5 days (total dose 150 mg/m2), and
cyclophosphamide 5 mg/kg daily for four days (total dose
20 mg/kg). Patients with non-Hodgkin’s lymphoma (NHL)
received Campath-1H 20 mg daily for five days, fludarabine20 mg/m2 for four days, and melphalan 140 mg/m2 for one
day only.
Stem cell source
The stem cell source for thalassemic patients was primarily
bone marrow, whereas peripheral blood stem cells (PBSC)
were the main stem cell source for CML patients. However in
aplastic anemia, bone marrow and PBSC were both used as
the stem cell source. Bone marrow was harvested from the
sibling donor on day 0 under general anesthesia by multiple
punctures in both iliac crests. Granulocyte-colony stimulat-
ing factor (G-CSF) mobilized PBSC were harvested from
sibling donors. All donors received G-CSF (Filgen) 10 mg/
kg/day for 5 days prior to PBSC harvest. PBSC were harvested
on day 2 and day 1 to achieve a standard dose of mono-
nuclear cells>4.0  108/kg body weight of patient by using a
COBE Spectra cell separator. The median apheresis time was
245 min (range 220—270 min). Bone marrow/PBSC harvests
were infused into the patient on day 0 under cover of steroids
and antihistamines.
GVHD prophylaxis
As prophylaxis against GVHD, cyclosporin (5 mg/kg/day IV in
two divided doses) and prednisolone (0.5 mg/kg/day) were
used from day 2 onwards. The IV dose of cyclosporin was
switched over to oral cyclosporin at the time of discharge
from hospital. The oral dose of the cyclosporin at the time of
switchover from IV dose was doubled and continued for 9
months. Thereafter cyclosporin was gradually tapered off
over the next three months (total duration one year). Cyclos-
porin dose was adjusted according to blood levels as well as
according to the renal status of the patient. Trough levels of
cyclosporin were maintained between 200 and 300 ng/ml.
Prednisolone was gradually tapered off until day +90 post-
SCT. Intravenous methotrexate (10 mg/m2) was given on days
+1, +3, +6, and +11 along with folinic acid rescue therapy.
Thalassemia patients also received IV immunoglobulin
500 mg/kg on day1 and then 250 mg/kg on days +8 and +22.
GVHD was diagnosed and graded both clinically and his-
tologically.12 GVHD was managed with escalating doses of
cyclosporin and steroids. In steroid-resistant GVHD, inter-
leukin-2 receptor antibodies and anti-thymocyte globulin
(ATG) were used. Follow-up bone marrow examinations were
done on days +30, +100, +180, and +360. The engraftment
was monitored with cytogenetic/molecular analysis and
change of blood group.
Statistical methods
Survival was calculated from the date of transplant to death
or last follow-up according to Kaplan—Meier and Cox (pro-
portional hazard) regression analysis methods. The analysis
was performed with Stats Direct software and MS excel
software.
Results
From July 2001 to September 2006, a total of 154 patients
received allogeneic SCT from HLA-matched sibling donors
at the Armed Forces Bone Marrow Transplant Centre,
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included were aplastic anemia (66), b-thalassemia (40),
CML (33), acute leukemia (8), and miscellaneous disorders,
which included Fanconi’s anemia (3), MDS (2), Gaucher’s
disease (1), and NHL (1).
One hundred and twenty patients were male and 34 were
female. The median age of the patients was 14 years (range
11/4 54 years). Eighty-eight donors were male and 66 were
female. Sixty-six patients were transplanted across gender.
Forty-nine patients had ABO mismatch transplants with
major ABO mismatch in 30 patients and minor ABO mismatch
in 19 patients. In 125 transplants both the patient and the
donor were CMV-positive, in 11 transplants the patient was
positive while the donor was negative, in 10 transplants the
patient was negative and the donor was positive, while in
eight transplants both the patient and donor were CMV-
negative. Forty-seven patients received bone marrow, 53
received PBSC, and 54 received both bone marrow and PBSC
harvest. Patient/donor characteristics and transplant proce-
dures are shown in Table 1.
Out of 154 patients who underwent SCT, 140 patients had
febrile episodes either alone or in association with other signs
and symptoms during different post-transplant recovery
phases. Relevant cultures and samples were taken in all
febrile patients to ascertain causative organisms. Out of
651 cultures from different sites, 150 culture specimens
(23.0%) were positive. Post-transplant infection was con-
firmed in 120 patients (77.9%) on the basis of clinical assess-
ment and microbiological, virological, and histopathological
analysis.
Bacterial infections were seen in 79/154 (51.3%) patients.
The majority of bacterial pathogens were Gram-negative
organisms (60.8%) compared with Gram-positive organisms
(39.2%). Infective organisms isolated in our patients in order
of frequency were coagulase-negative Staphylococcus
(CoNS) in 23 patients (14.9%), followed by Pseudomonas
spp in 21 patients (13.6%), Klebsiella spp in nine patients
(5.8%), MRSA in eight patients (5.2%), Acinetobacter spp in
eight patients (5.2%), E. coli in seven patients (4.5%), and
Enterobacter spp in three (1.9%) patients. Mycobacterium
tuberculosiswas seen in four patients (2.6%). The majority of
bacterial pathogens were isolated from either blood drawn
from a peripheral vein or fluid collected from the central
venous line (heparinized saline used to lock the line when not
in use).
Fungal infections were seen in 23 patients (14.9%). Among
fungal infections, Candida albicans was isolated from blood,
central venous line fluid, and sputum in 16 patients (10.4%).
Aspergillus spp was isolated from blood, tissues, sputum,
BAL, and pus in six patients (3.9%). Pneumocystis jiroveciwas
isolated from BAL in one patient (0.6%).
Plasmodium falciparum was isolated from peripheral
blood in one patient (0.6%). CMV infection was documented
in 28 patients (18.2%). CMV disease (two enterocolitis, four
pneumonia) was seen in six patients (3.9%). Vesicular erup-
tions in dermatomal pattern suggestive of herpes zoster
infection were clinically seen in six patients (3.9%). The
frequencies of infections seen in our patients are shown in
Table 2.
Infection-related morality was observed in 20 patients
(13.0%). The various infective causes of mortality were
Pseudomonas septicemia, disseminated aspergillosis, CMVdisease, and disseminated tuberculosis. Fatal Pseudomonas
septicemia was observed in the early recovery phase whereas
fatal fungal and CMV infections were observed in the mid and
late recovery phases. Mortality related to tuberculosis was
observed in the mid recovery phase. Out of 21 patients who
developed Pseudomonas infection, nine died of septicemia
during the first 30 days post-SCT.
Four patients out of six who developed Aspergillus infec-
tion died of disseminated disease involving the lungs, liver,
and subcutaneous tissues. Two patients developed Aspergil-
lus infection during the mid recovery phase. Of these, one
patient developed bilateral pneumonitis and nodular ulcer-
ating lesions in the lower abdomen and right thigh on day +45;
the tissue biopsy and culture from the site revealed the
growth of Aspergillus fumigatus. The other patient devel-
oped grade III acute GVHD, which was complicated by pul-
monary and hepatic aspergillosis at day +74; tissue biopsy and
culture confirmed the growth of Aspergillus fumigatus. The
remaining two patients developed disseminated aspergillosis
during the late recovery phase at day +123 and day +187.
Both patients had chronic extensive GVHD, which was com-
plicated by jaundice, hepatomegaly, and subcutaneous nod-
ular swellings involving the thighs. Tissue biopsy specimens
confirmed the growth of Aspergillus fumigatus. All patients
received amphotericin B initially against Aspergillus infec-
tion. Two patients were treated with amphotericin B com-
bined with itraconazole, while one patient was treated with
voriconazole and the other received caspofungin. None of
these patients responded to antifungal therapy and they died
on days +59, +72, +135, and +201 post-SCT.
Out of six patients with CMV disease, two developed
enterocolitis during the mid recovery phase at days +42
and +59. CMV pneumonitis was observed in four patients
during the late recovery phase at days +98, +116, +127,
and +139 post-SCT. All patients were treated with ganciclovir,
however none responded to antiviral therapy and they died at
days +54, +67, +110, +123, +133, and +155 post-SCT.
A total of four patients had tuberculous infection at days
+21, +30, +92, and +241 post-SCT. Out of these, one patient
developed tuberculous lymphadenopathy with superior med-
iastinal widening at day +92. Mediastinoscopic tissue biopsy
and cultures were positive for M. tuberculosis with caseating
granulomatas. The patient did not respond to treatment and
died on day +124 post-transplant. The frequency of infections
in the early, mid, and late recovery phases, and the sites of
infection are shown in Tables 3 and 4.
Aspergillus infection was observed in aplastic anemia and
CML only, whereas Candida infection was more common
among thalassemic patients. CMV disease was more frequent
in thalassemia and CML patients. Apart from these, the other
infections were evenly distributed in all the hematological
disorders as shown in Table 5.
In our study, at the end of 5 years, the overall survival and
disease-free survival were 72.7% and 70.7%, respectively,
with a median follow-up of 56.2  3.1 months. Disease-free
survival for the different hematological disorders in our
patients as compared to those reported by the Center for
International Blood and Marrow Transplant Research
(CIBMTR) and EBMT are shown in Figure 1. Overall mortality
was observed in 27.3% (42/154). Mortality related to infec-
tions was 13.0% (20/154). Post-transplant fatal infections in
different hematological disorders are shown in Table 6.
208
K
.
U
llah
e
t
al.
Table 1 Patient/donor characteristics and transplant procedures
All disorders
(n = 154)
Thalassemia
(n = 40)
Aplastic anemia
(n = 66)
CML (n = 33) Acute leukemia
(n = 8)
Misc. (n = 7)a
Patient Donor Patient Donor Patient Donor Patient Donor Patient Donor Patient Donor
Sex
Male 120 88 28 16 52 37 30 25 6 5 4 5
Female 34 66 12 24 14 29 3 8 2 3 3 2
M/F ratio 3.5:1 1.3:1 2.3:1 0.6:1 3.7:1 1.3:1 10:1 3.1:1 3:1 1.6:1 1.3:1 2.5:1
Age
Median age (years) 14 17 4 5.5 17 18 25 27 21 15 10 14
Range (years) 11/454 1—54 11/414 1—18 5—38 3—45 7—54 7—54 5—36 5—36 2—40 8—35
CMV status
Patient (+): donor (+) 125 25 54 33 6 7
Patient (+): donor () 11 5 6 - - -
Patient (): donor (+) 10 6 2 - 2 -
Patient (): donor () 8 4 4 - - -
Risk stratification Pesaro risk class Camitta
classification
Risk group Risk group Risk group
Class I 25 VSAA 52 Standard risk 23 Relapse disease
(8); high risk (0)
FA (3); MDS (2);
Gaucher’s disease
(1); NHL (1)
Class II 10 SAA 14 High risk 10
Class III 5
ABO incompatibility
Major 30 6 14 8 1 1
Minor 19 10 5 2 0 2
Conditioning regimen Class I and II: Bu
14/Cy 200; class III:
hydroxyurea,
azathioprine, Flu,
Bu 14/Cy 160
Cy 200 mg/kg Bu 16/Cy 200 Bu 16/Cy 200 FA: Flu, ATG, Cy;
Gaucher’s disease:
Bu 14/Cy 200;
MDS: Bu 16/Cy
200; NHL:
Campath, Flu, Mel
ATG 45 mg/kg Bu 16/Cy 120
Source of stem cell
BM 47 35 6 1 - 5
PBSC 53 5 8 30 8 2
PBSC + BM 54 - 52 2 -
Transplant
First 154 40 66 33 8 7
Second 6 3 3 - -
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Table 2 Frequency of infections, number of febrile epi-
sodes, and microbiological culture yield
Patients (%)
Infections
Bacterial infections a 79/154 (51.3)
Fungal infectionb 23/154 (14.9)
Cytomegalovirus disease 6/154 (3.9)
Herpes infections 6/154 (3.9)
Tuberculosis 4/154 (2.6)
Pneumocystis jiroveci 1/154 (0.6)
Malaria 1/154 (0.6)
Total 120/154 (77.9)
Febrile episodes 140/154 (90.9)
Microbiological culture yield 150/651 (23.0)
a Coagulase-negative Staphylococcus (23), Pseudomonas aeru-
ginosa (21), Klebsiella spp (9), methicillin-resistant Staphylococ-
cus aureus (8), Acinetobacter spp (8), Escherichia coli (7),
Enterobacter spp (3).
b Candida albicans (16), Aspergillus spp (6), Trichosporon bei-
gelii (1).
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Opportunistic infections of varying severity with bacterial,
viral, and fungal organisms occur in >90% of patients after
allogeneic SCT and contribute significantly to morbidity and
mortality after engraftment.2 Fatal opportunistic infections
have been reported in 4—15% of related transplant recipients
and 12—28% of unrelated transplant recipients.13 Data from
18 different transplant centers in the UK for 1825 transplant
patients showed a 6.2% incidence of severe infections requir-
ing readmission to hospital less than 100 days following bone
marrow transplant (BMT). The majority of infections
occurred in recipients of allogeneic SCT (58%) and proved
fatal in 3.7% of all patients. Common organisms encountered
were CMV, P. jiroveci, Streptococcus pneumoniae, Pseudo-
monas spp, and Aspergillus spp with mortalities of 84%, 67%,
33%, 85%, and 87%, respectively.14
Bacterial infections are frequently seen during the post-
transplant neutropenia phase. During the early post-trans-
plant period, damage to the mucosal surfaces and neutro-
penia allow commensal bacteria easy entry into the systemic
circulation. Routine frequent use of indwelling central
venous catheters in transplant patients results in local infec-
tion and sepsis. The most common pathogens are Gram-
positive bacteria, especially CoNS. Besides these, Gram-
negative organisms including E. coli, Klebsiella spp, and P.
aeruginosa are the most common bacterial pathogens during
the early post-transplant neutropenic phase.15 Usually anti-
biotic treatment alone is adequate, but occasionally removal
of the catheter is necessary if the infection is not responsive.
The classic approach for the management of these infections
has been a semi-synthetic penicillin/extended-spectrum
cephalosporin with an aminoglycoside. These antibiotics
are used empirically at first indication of fever in neutropenic
patients.16
Over the past two decades the percentage of infections
caused by Gram-negative organisms has steadily decreased
from 70% to 30%, and Gram-positive bacteria now account for
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Table 3 Post-transplant opportunistic bacterial, fungal, viral, and parasitic infections by recovery phase
Organisms Early recovery phase
(pre-engraftment)
(<30 days)
Mid recovery phase
(post-engraftment)
(30—100 days)
Late recovery phase
(>100 days)
Total
CoNS 13 5 5 23
MRSA 5 2 1 8
Pseudomonas aeruginosa 14 4 3 21
Klebsiella pneumoniae 5 3 1 9
Escherichia coli 4 2 1 7
Acinetobacter spp 3 3 2 8
Enterobacter spp - 3 - 3
Mycobacterium tuberculosis 2 1 1 4
Pneumocystis jiroveci 1 - - 1
Candida albicans 11 3 2 16
Aspergillus spp - 3 3 6
Trichosporon beigelii 1 - - 1
Cytomegalovirus - 3 3 6
Varicella zoster virus - - 6 6
Plasmodium falciparum 1 - - 1
Total number of infections 60 32 28 120
CoNS, coagulase-negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus.70% of bacterial infections compared with 30%, 25 years
ago.17,18 Data from developing countries, though limited,
show that 40—50% of patients develop bacterial infections;
Gram-negative bacteria are still the major organisms,
although incidence of Gram-positive organisms seems to
be on the increase, consistent withWestern data.19,20 George
et al.21 from India reported 36.9% bacterial infections, 45.7%
viral infections, and 11.1% fungal infections in transplant
patients. Themajor bacterial pathogens were Gram-negative
organisms (72.7%) compared with Gram-positive organisms
(27.3%). Common Gram-negative organisms were Pseudomo-Table 4 Post-transplant infections by site of infection
Organisms Blood CV line
fluid
Nasal
swab
Throat
swab
CoNS 13 10 - -
MRSA 3 3 - -
Pseudomonas aeruginosa 8 8 1 -
Klebsiella pneumoniae 2 2 - -
ESBL-producing Klebsiella 1 - - -
Escherichia coli 4 - - 3
Acinetobacter spp - 4 2 -
Enterobacter spp - 2 - 1
Mycobacterium tuberculosis - - - -
Pneumocytis jiroveci - - - -
Candida albicans 6 6 - -
Aspergillus spp 2 - - -
Trichosporon beigelii - - - -
Cytomegalovirus - - - -
Varicella zoster virus - - - -
Plasmodium falciparum 1 - - -
Total 40 35 3 4
CV line, central venous line; BAL, bronchoalveolar lavage; CoNS, coagu
lococcus aureus; ESBL, extended-spectrum beta-lactamase.nas, E. coli, and Klebsiella, while CoNS were the main Gram-
positive organisms.
In our series, bacterial infections were observed in 51.3%
of patients during the early post-transplant period (Gram-
negative infections 60.8% and Gram-positive infections
39.2%). Pseudomonas aeruginosa and CoNS were major bac-
terial pathogens.
Tuberculosis has been demonstrated to be a significant
problem following allogeneic SCT in endemic countries, with
an incidence of 0.1—5.5%.22 The incidence of active tuber-
culosis after allogeneic SCT has been reported in 3.1% ofSputum BAL Pleural
fluid
Pus Tissue Clinical
diagnosis
Total
- - - - - 23
2 - - - - 8
1 - - 1 2 21
4 - - - - 8
- - - - - 1
- - - - - 7
- - - - 2 8
- - - - - 3
- 1 2 - 1 4
- 1 - - - 1
4 - - - - 16
1 1 - 1 1 6
- 1 - - - 1
- - - - 6 6
- - - - - 6 6
- - - - - 1
12 4 2 2 12 6 120
lase-negative Staphylococcus; MRSA, methicillin-resistant Staphy-
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Table 5 Post-transplant opportunistic infections by disease
Organisms Aplastic anemia b-Thalassemia CML Acute leukemia Misc. Total
CoNS 11 5 4 2 1 23
MRSA 2 3 2 1 0 8
Pseudomonas aeruginosa 10 2 4 3 2 21
Klebsiella pneumoniae 4 2 2 0 1 9
Escherichia coli 1 2 2 1 1 7
Acinetobacter johnsonii 3 3 1 1 0 8
Enterobacter spp 2 1 0 0 0 3
Mycobacterium tuberculosis 1 1 2 0 0 4
Pneumocystis jiroveci 0 0 0 1 0 1
Candida albicans 1 9 3 1 2 16
Aspergillus spp 3 0 3 0 0 6
Trichosporon beigelii 0 0 0 1 0 1
Cytomegalovirus 1 3 2 0 0 6
Varicella zoster virus 2 3 1 0 0 6
Plasmodium falciparum 1 0 0 0 0 1
Total 42 34 26 11 7 120
CML, chronic myeloid leukemia; CoNS, coagulase-negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus.patients in Korea.23 Similarly in Turkey, where tuberculosis is
endemic, a 30—40 times higher incidence has been reported
in BMT patients compared to the general Turkish popula-
tion.24 A study from Taiwan shows a trend towards increased
risk of having pulmonary tuberculosis in allogeneic SCT as
compared to autologous SCT (4.8  1.8% vs. 0).25 In 2001,
George et al.26 and Chandy et al.27 from Vellore, India
reported 1.38% and 2.2% incidence of tuberculosis in trans-
plant recipients, respectively. However, updated data from
the same center in 2006 show 1.7% tuberculosis in transplant
patients.21 In our series, four (2.6%) patients developedFigure 1 HLA-identical sibling hematopoietic stem cell transpla
transplant (DFS) data, 1998—2004; Marcelo et al., Report on state of
2006;12:5—10. **EBMT Working Party on Pediatric Diseases, Pesaro gr
cure of thalassemia by bone marrow transplantation. Bone Marrow Tr
Transplant Centre Pakistan, post-transplant (DFS) data, 2001—2006.tuberculosis. Of these, two patients developed the disease
in the early post-transplant period whereas the other two
developed tuberculosis in the mid and late recovery phases.
These infections were most probably due to reactivation of
previous tuberculosis infection.
PCP accounts for fewer than 10% of the cases of inter-
stitial pneumonia in patients with allogeneic SCT.28 One of
our patients developed PCP pneumonia during the first
post-transplant month. Because of early diagnosis and
initiation of treatment this patient made a complete
recovery.ntation disease-free survival (DFS) by disease. *CIBMTR post-
the art in blood and marrow transplantation. CIBMTR Newsletter
oup post-transplant (DFS) data, 1982—2001; Lucarelli et al., The
ansplant 2001;28(Suppl 1):S11—3. ***Armed Forces Bone Marrow
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Table 6 Causes of death by disease
Disease Relapse aGVHD
grade IV
cGVHD VOD ICH ARF Septicemia Fungal
infection
CMV TB Total
Aplastic anemia (n = 66) - 1 2 2 - 4 4 2 1 - 16
b-Thalassemia (n = 40) - 1 - 1 - - 2 - 3 1 8
CML (n = 33) - 1 1 2 - - 2 2 2 - 10
Acute leukemia (n = 8) 5 - - - - - - - - - 5
NHL (n = 1) - - - - - - - - - - -
MDS (n = 2) - - - 1 - - - - - - 1
Fanconi’s anemia (n = 3) - - - - 1 - - - - - 1
Gaucher’s disease (n = 1) - - - - - - 1 - - - 1
Total (n = 154) 5 3 3 6 1 4 9 4 6 1 42
Overall mortality 27.3% (42/154); infection-related mortality 13.0% (20/154); non-infection-related mortality 14.3% (22/154).
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; VOD, veno-occlusive disease; ICH, intracranial
hemorrhage; ARF, acute renal failure; CMV, cytomegalovirus; TB, tuberculosis; CML, chronic myeloid leukemia; NHL, non-Hodgkin’s
lymphoma; MDS, myelodysplastic syndrome.Nosocomial fungemia due to Candida spp and systemic
candidiasis are serious post-transplant complications asso-
ciated with high morbidity and mortality. Antifungal prophy-
laxis with fluconazole during the early post-transplant period
has been proved beneficial.6 From January 1997 to December
1999, out of 204 allogeneic marrow transplants performed at
the University of South Carolina, USA, 14 patients developed
nosocomial candidemia while receiving fluconazole (100—
200 mg daily) prophylactically, and the incidence of hema-
togenous candidiasis was only 6.8%.29
Invasive fungal infections (IFI) with Aspergillus spp are a
significant cause of morbidity and mortality after SCT.30,31
More than half of transplant patients affected by aspergillosis
die from their fungal infections. Reactivation in transplant
patients has been estimated to be 30—50% and is associated
with a poor prognosis.32,33 Retrospective analysis of data
from 48 transplant patients shows a 33% overall risk of
Aspergillus relapse with 88% mortality.34 Between April
1980 and December 2002, a total of 1453 patients were
transplanted at HMR Quebec, Canada. Five hundred and
twenty-five patients had 939 episodes of blood stream infec-
tions. Out of these, aspergillemia was observed 23 times in 21
patients.35 Voriconazole has been used as first line treatment
of aspergillosis and has been shown to be more effective and
better tolerated than amphotericin B. Despite a substantial
number of side effects, voriconazole is widely used after
SCT.36—38 Studies from Asian countries like Israel and India
have observed an increasing incidence of fungal infections
from BMT units.39,40 In our series, fungal infections were
observed in 14.9% of patients. Candida spp was the major
fungal pathogen (69.5%) as compared to Aspergillus spp
(26%). The overall incidence of fungal infections in our
patients is similar to that found in other Asian countries like
India; however, aspergillosis was a more common infection in
transplant recipients in Vellore, India, whereas candidiasis
was the more common infection in our patients. We used
fluconazole prophylaxis routinely at a dose of 50—100 mg
daily. Sixteen patients (10.4%) developed Candida spp infec-
tion during the early post-transplant period. All patients
responded to amphotericin B and no fatality was seen. Six
of our patients developed disseminated aspergillosis in the
mid and late recovery phases and this proved fatal in fourpatients. All patients were initially treated with amphoter-
icin B and itraconazole. Patients who did not respond also
received voriconazole—caspofungin.
CMV infection is the most common fatal infection follow-
ing a BMT, accounting for 15—20% mortality. The incidence of
CMV infection in 785 BMT patients in one institution has been
reported to be 49% in autologous transplants and 46% in
allogeneic transplants.41 CMV interstitial pneumonitis is
the most common infectious complication.15 Ganciclovir
alone or in combination with immunoglobulins has been
shown in several studies to result in resolution of pneumonitis
in 50—70% of patients.42,43 George et al.21 reported 21.3%
CMV infection and 20.5% CMV disease in transplant patients,
with 90% mortality. In our series, CMV infection was docu-
mented in 28/154 (18.2%) patients and CMV disease was seen
in 3.9% of patients with 100% mortality. One patient devel-
oped disease during the early recovery phase while two
developed disease during the mid recovery phase and three
patients developed disease during the late recovery phase.
One hundred and thirty-six patients and 135 donors were CMV
IgG-positive during pre-transplant workup. Five out of six
patients also had extensive chronic GVHD and were on heavy
immunosuppression. Four patients were treated with ganci-
clovir, while in two patients diagnosis was confirmed after
death. Unfortunately none of these patients survived.
Varicella zoster virus (VZV) infection is most problematic
in sero-positive patients during the mid and late recovery
phases, usually due to reactivation of the virus. Its usual
manifestation is dermatomal vesicular eruptions at a median
of 5 months after BMT and occurs in 25—40% of patients.44
Four of our patients developed herpes zoster infection during
the late recovery phase, between 1 and 2 years post-SCT, and
were successfully treated with acyclovir.
In summary, infections were documented in 77.9% of our
patients with 13.0% mortality. The major causes of mortality
were CMV enterocolitis/pneumonia, disseminated aspergil-
losis, pseudomonas septicemia, and disseminated tubercu-
losis with mortalities of 100% (6/6), 66.7% (4/6), 42.9% (9/
21), and 25% (1/4), respectively.
The high rate of mortality from CMV and Aspergillus
infections in our series was probably due to disseminated
infections as a result of the heavy immunosuppression that
Post-transplant infections: single center experience 213these patients were receiving due to GVHD. None of our
patients developed protozoal or helminthic infections apart
from a single case of malaria. This could be due to our
effective prophylaxis.
Pakistan is a developing country in Southeast Asia where
tuberculosis and malaria are prevalent and the majority of
the population is sero-positive for CMV. We were apprehen-
sive about an increased incidence of tuberculosis, malaria,
and CMV disease in our patients when we started the bone
marrow transplant program in our country. We screened all
patients and donors for these diseases.
One of our major concerns is the limited availability of
newer, less toxic antifungal and antiviral drugs. Another
major concern is poor patient compliance with treatment
not uncommon in developing countries such as Pakistan.
There is a need to improve social services in our country
as well as to educate the patients and their families to
comply with treatment during the post-transplant period.
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